文献速递淋巴瘤

基因组微阵列识别的额外病变与低危慢性淋巴细胞白血病患者较差结局相关

Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients.
PubMed 文献 · Br J Haematol · 2023-06-26

本研究探讨基因组微阵列(GM)在新诊断低危慢性淋巴细胞白血病(CLL)患者预后细化中的作用,低危定义为标准4探针荧光原位杂交(FISH)分析仅显示孤立del(13q)或无病变。与FISH相比,GM在119例患者中的27例(22.7%)检测到额外病变,FISH与GM的一致率为87.4%。GM检测到的额外病变与年龄>65岁(p=0.047)、晚期Binet分期(p=0.001)、CLL-IPI评分(p<0.001)、复杂核型(p=0.004)以及多因素分析中较差的首次治疗时间(p=0.009)相关。

要点

  • 在标准FISH定义的低危CLL患者中,GM额外检出27/119例(22.7%)病变。
  • GM额外病变与较差首次治疗时间独立相关(多因素分析p=0.009)。
  • 在TP53野生型且IGHV突变亚组中,GM额外病变仍与较差首次治疗时间相关(p=0.025)。

核心结论

  • 在具有低危特征的CLL患者中,GM识别的额外病变有助于识别结局较差的患者亚群,这些患者可考虑风险适应随访及临床试验中的早期靶向治疗。

研究设计与样本

  • 研究纳入119例新诊断低危CLL患者,低危定义为标准4探针FISH分析仅显示孤立del(13q)或无病变,比较FISH与GM检测结果。

主要发现

  • 与FISH相比,GM在27/119例(22.7%)患者中检测到额外病变,FISH与GM的一致率为87.4%。
  • 细胞遗传学显带分析(CBA)与GM之间观察到45/119例(37.8%)不一致结果,主要归因于每种技术的内在特征。
  • GM额外病变与年龄>65岁(p=0.047)、晚期Binet分期(p=0.001)、CLL-IPI评分(p<0.001)、复杂核型(p=0.004)相关。
  • 多因素分析中,GM额外病变与较差的首次治疗时间相关(p=0.009)。
  • 在TP53野生型且IGHV突变患者亚组中,GM额外病变与较差的首次治疗时间显著相关(p=0.025)。

临床怎么用

  • 作者认为,在低危CLL患者中,GM识别的额外病变有助于识别结局较差的患者亚群,可考虑风险适应随访及临床试验中的早期靶向治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We explored the relevance of genomic microarrays (GM) in the refinement of prognosis in newly diagnosed low-risk chronic lymphocytic leukaemia (CLL) patients as defined by isolated del(13q) or no lesions by a standard 4 probe fluorescence in situ hybridization (FISH) analysis. Compared to FISH, additional lesions were detected by GM in 27 of the 119 patients (22.7%). The concordance rate between FISH and GM was 87.4%. Discordant results between cytogenetic banding analysis (CBA) and GM were observed in 45/119 cases (37.8%) and were mainly due to the intrinsic characteristics of each technique. The presence of additional lesions by GM was associated with age > 65 years (p = 0.047), advanced Binet stage (p = 0.001), CLL-IPI score (p < 0.001), a complex karyotype (p = 0.004) and a worse time-to-first treatment in multivariate analysis (p = 0.009). Additional lesions by GM were also significantly associated with a worse time-to-first treatment in the subset of patients with wild-type TP53 and mutated IGHV (p = 0.025). In CLL patients with low-risk features, the presence of additional lesions identified by GM helps to identify a subset of patients with a worse outcome that could be proposed for a risk-adapted follow-up and for early treatment including targeted agents within clinical trials.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rigolin GM, Traversa A, Caputo V, et al. Additional lesions identified by genomic microarrays are associated with an inferior outcome in low-risk chronic lymphocytic leukaemia patients. Br J Haematol. 2023. PMID: 37357817. doi:10.1111/bjh.18946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。